Original Research Article

Prevalence of carbapenem-resistant bugs in rectal swabs from patients/working staff in 2 3 Medical Intensive Care Units. 4 5 Abstract 6 Introduction 7 With increased exposure to antibiotics, changes in the endogenous microbiota due to constant 8 pressure of antibiotic selection can happen silently, resulting in the culmination of multidrug 9 resistant strains. As the normal microflora is commonly implicated in human infections, these 10 resistant strains can lead to nosocomial infections or a limited outbreak. This study was 11 12 undertaken to investigate the carriage of carbapenem-resistant isolates in the rectal swabs of 13 patients admitted in Medical Intensive Care Units (MICU) of our hospital. Methods 14 Between December 2016-february 2017, rectal swab samples from 178 patients and 31 staff 15 members of MICU were collected, isolates identified and tested for carbapenemase activity. 16 Patients who were detected with carbapenemase activity in rectal swabs were further 17 analyzed for carbapenemase activity in clinical samples. The activity of isolates (if any) was 18 co-related with the clinical samples in patients and real time PCR (Stratagene) was carried 19 out for genotype analysis. 20 Results 21 Of the 209 strains obtained from srectal swabs, 29 (13.8%) isolates from patients and none 22 from staff demonstrated carbapenemase activity. Thirteen oQut of these 29-Thirteen patients 23 were carriers and none of their clinical samples showed any growth. Twelve patients showed 24 similarity i.e. rectal swabs and clinical samples showed similar type of Gram negative 25 isolates with carbapenemase activity. No correlation was observed in 4 patients. Real time 26 PCR analysis for Klebsiella pneumoniae carbapenemase (KPC) and New Delhi metallo-beta-27 28 lactamase 1 (NDM) genes in twelve patients showing similar isolates has shown that none of 29 the isolates tested positive for KPC whereas nine isolate pairs showed NDM gene expression indicating endogenous infections. 30 31 Conclusion

Screening for carriage of carbapenem resistant enteric Gram negative bacteria in patients
 undergoing elective or emergency gastrointestinal surgical procedures can guide clinicians

1

about the antibiotic choices as these groups of patients are at high risk of possibleendogenous infections.

36

Key words: Healthcare associated infections, Carbapenem resistance, Multi-drug resistance,
Intensive care unit.

39

40 Introduction

41

Nosocomial' or 'healthcare associated infections' (HCAI) are classified as infections which 42 manifest in the patient post 48h of hospital admission and are absent at the time of admission 43 (1). Such kind of infections occurkind of infections occurs when the patient is availing the 44 healthcare facilities and may sometimes occur even after patient discharge. Moreover, 45 nosocomial infections also comprise the occupational infections that occur among the 46 medical staff (1). Nosocomial infections are mainly caused by diagnostic or therapeutic 47 interventional procedures including catheters and ventilators, and are also influenced by other 48 factors including patient's immune system, underlying illness, antibiotic exposure, hospital 49 environment and bacteriological flora prevalent within a hospital (2). It has been reported that 50 7% of hospitalized patients in developed and 10% in developing countries can acquire one of 51 the HCAI (3). The patients in Intensive Care Units (ICUs), surgical units, neonates and 52 undergoing organ transplant are comparatively at higher risk of undergoing HCAIs (1). The 53 rate of HCAIs in ICU patients has been predicted as high as 51% according to Extended 54 Prevalence of Infection in Intensive Care (EPIC II) study (3). 55

56 Bacteria are the most common pathogens responsible for nosocomial infections and the pathogen source can be exogenous or endogenous. 10% of the pathogens causing HAIs arise 57 from endogenous microflora of the patient (4). The patient becomes vulnerable to infections 58 by its own endogenous natural flora when the immune system of the patients becomes very 59 weak because of underlying illness and the continuous antibiotic exposure. The infections 60 61 which arise mainly from patient's own microflora are surgical site infections and catheter associated urinary tract infections (CAUTIs) (5)(6). These pathogens cause infections if they 62 travel to other body parts from the parts where they are usually found. With increasing 63 exposure to antibiotics, the endogenous microbiota faces constant pressure of antibiotic 64 selection and can result in the emergence of multidrug resistant endogenous strains. These 65 multi-drug resistant nosocomial infections are associated with prolonged hospital stay, socio-66 economic implications, increased morbidity and mortality rates (7). This surveillance study 67

Comment [EM1]: Replace with (5-6).

was undertaken to investigate the carriage of carbapenem-resistant isolates in the rectal swabsamong patients admitted in MICU in our hospital.

70

71 Materials and methods

72 Study design

This study was conducted on patients suffering from different bacterial infections and
admitted to our hospital for treatment <u>during the period</u> between Dec. 2016 to Feb. 2017. The
study was conducted as per the ethical principles of Declaration of Helsinki.

76

77 Study population

- We enrolled 209 patients in this study. The number of patients included in the study 78 were 209. Specimens were collected from 301 subjects from MICU including the 79 hospitalized patients and the staff. Rectal swabs (perirectal swabs were not allowed) were 80 collected from all the subjects and immediately transported to the lab. Cotton swabs were 81 82 used for collecting rectal samples and were done by inserting and rotating the 1cm swab into the rectum. Following sampling, the swab was placed in the tube which contained 1ml sterile 83 transport medium and the tube was vortexed for 1 min at maximum speed in the lab. All 209 84 rectal swab specimens were subjected to analysis. Clinical samples were obtained and 85 analyzed only from the patients who were detected with carbapenemase producing isolates in 86 rectal swabs. 29 pairs of carbapenemase producing rectal swabs were analyzed in parallel 87 with the clinical isolates using qPCR-based analysis. 88

89

91

90 Culture-based quantification of carbapenem resistant isolates

Viable bacterial counts were performed for transport medium containing bacteria (100µl) by serial 10-fold dilutions in 0.9% saline. This was followed by plating of inoculum on tryptose soy agar plates supplemented with 5% sheep blood to quantitate the total culturable aerobic bacteria (TAB), and plating on CHROMagar KPC plates (HyLabs, Rehovot, Israel) for determining carbapenem resistant bacteria (CRB). After 18h of growth at 37°C, viable bacterial counts were done and the CRB to TAB ratio (CFU/ml) was determined. **Comment [EM2]:** 209 patients and the rest were personel? Please define.

Comment [EM3]: Please provide the method of identification of the bacterial isolates. You only describe the culturing method and the method to identify the production of KPC carbapenemase.

99 Quantitative real-time PCR

100 qPCR was performed for analyzing the KPC or NDM producers using KPC and

- 101 NDMspecific primers and miScript-SYBR Green Mix (Qiagen).
- 102
- 103 Results
- 104

105 Demographic characters

A total of 301 subjects from MICU including the patients suffering from different 106 infections and the working staff were screened for this study. Of the 309 subjects screened, 107 rectal swabs were collected from 209 subjects who consisted of 31 members from staff and 108 178 patients. Overall, the number of males (n=113, 54%) were more compared to females 109 (n=96, 46%). The mean age was 47 ranging from 27 to 75 years. The common co-morbidities 110 associated with patients at the time of hospitalization were hypertension (n=54, 24%), 111 112 diabetes mellitus (n=46, 22%) and chronic liver disorders (n=19, 9%). 34.8% (62/178) of the patients were diagnosed with hospital acquired infections (HAIs). 27 patients had acquired 113 HAIs inside MICU and 35 had acquired in wards which were shifted to MICU. 114

115 In vitro susceptibility analysis

116 Culture susceptibility analysis has shown that twenty-nine (13.8%) isolates 117 demonstrated carbapenemase activity among 209 screened rectal swab isolates. All the rectal 118 swab samples from the staff had susceptible microbiota and carbapenem resistance was not 119 reported in any of the isolates. All the 29 (13.8%) carbapenemase producing isolates were 120 from the patients included in the study. The isolates with carbapenemase activity in 121 descending order are *E. coli* (17), *K. pn<u>eumemoniae</u> (7), <i>P aeruginosa* (3) and *A. baumannii* 122 (2).

Only 29 patients who were detected with carbapenemase activity in rectal swabs were 123 further analyzed for carbapenemase activity in clinical samples. The clinical samples 124 obtained from these 29 patients and processed further were urine (16), sputum (8), fluid (3) 125 126 and blood (2). Analysis of rectal swabs and clinical samples have shown that thirteen out of 29 patients were carriers as isolates were obtained from rectal swabs only and none of the 127 128 clinical samples showed any growth. 16 patients showed growth in both rectal swabs and clinical samples. Of the 16 patients showing growth, twelve patients showed similarity i.e. 129 130 rectal swabs and clinical samples showed similar isolates. The isolates from rectal swabs

Comment [EM4]: Please provide the primers used for identification or proper references of this method. You previously described the identification of KPC carbapenemase with chromAgar plates. How many samples were analyzed by qPCR?

Comment [EM5]: Which method did you use? Kirby-Bauer or MIC? Please refer the method in Material and Methods. Did you use CLSI or Eucast breakpoints? Please also define.

Comment [EM6]: Please define which type of carbapenemase was detected. A. baumanii carbapenem resistance is related to OXA rather than KPC or NDM, whereas Pseudomonas is connected with NDM carbapenemase. Klebsiellae has shown both NDM. KPC and OXA. were different from the clinical samples in four patients. For details of the isolates reportedin rectal swabs and clinical samples and their source specimens, refer to Table 2 and 3.

133

134 Genotype analysis

Real time PCR (Stratagene) was carried out for the amplification of NDM and KPC genes. Out of the 12 samples showing similar isolates in rectal swabs and clinical samples, 10 pairs revived and all of them tested negative for KPC. 09 pairs tested positive for NDM gene in both rectal swab and clinical samples proving that patient had endogenous infection in these 9 patients. Only 1 pair showed dis-similar results as rectal swab tested negative for NDM whereas clinical sample tested positive for NDM.

141

142 Discussion

The human gastrointestinal tract serves as an endogenous reservoir of pathogens for 143 various opportunistic pathogens causing various infections including urinary tract infections 144 (UTI) and nosocomial infections like skin & soft tissue infections (SSIs) (1). However, with 145 increased consumption of antibiotics, intestinal microflora faces constant pressure of 146 antibiotic selection, which has resulted in the emergence of multidrug resistant endogenous 147 148 strains. Carbapenems are the most effective modified beta-lactam antibiotics with a broad spectrum of activity against these multi-drug resistant strains (8) (9). Their unique molecular 149 150 structure which combines carbapenem with the beta-lactam ring confers them exceptional stability against most beta-lactamases including AmpC (ampicillin and carbenicillin) and 151 152 extended spectrum beta-lactamases (ESBLs) (9). Being highly effective against wide range of 153 bacterial species, carbapenems are considered the most reliable last-resort treatment for 154 bacterial infections. However, the excessive carbapenem prescription has led to the 155 emergence and spread of carbapenem-resistant strains and created a global public health crisis (10) (11). 156

This widespread carbapenem resistance has not even spared the normal microbiota of 157 158 patients. In our study, 16.3% of the isolates from the rectal flora of the admitted patients in MICU demonstrated carbapenemase activity. Rai et al. (12) has reported that 9.9% isolates 159 160 demonstrated carbapenemase activity in a prospective surveillance study undertaken to investigate the carriage of carbapenem-resistance 242 161 among 162 screened Enterobacteriaceae isolates in the gastrointestinal tract among patients attending the outpatient clinic in a tertiary care center of East Delhi, India. Similarly, Das et al. (13) has 163 reported that neonates with endogenous Gram negative bacilli in the gut had a higher 164

Comment [EM7]: Please provide information for each group (what bacteria were NDM positive, and KPC positive). incidence of clinical sepsis than those without. Moreover, in 50% of cases, the genotypes ofthe organisms found in the blood were indistinguishable from their gut counterpart.

The similar carbapenem-resistant organisms identified in clinical and rectal swabs 167 from 31% of patients show that the opportunistic endogenous flora translocate to the ideal 168 and favorable surfaces and turn pathogenic taking advantage of suppressed host immune 169 170 system, mucosal barrier permeability, stress or co-morbidities, in vivo devices, surgical 171 procedures, etc. Moreover, the kind of patient flora can hint at the antimicrobial susceptibility profile of patient and guide physicians about the antibiotic choices. Out of 29, 13 patients 172 were also carriers of carbapenem-resistant isolates. This resistant endogenous flora may 173 remain silent for months in the gut of the carrier without leading to any visible symptoms or 174 translocate to other favorable surfaces, become opportunistic and induce healthcare-175 associated infections, or may lead to limited outbreaks through cross-transmission to other 176 individuals (14) (4). 177

178

179 Conclusion

An important component of infection control program is active surveillance of drug 180 resistant strains, including ESBL-producing strains and carbapenem-resistant strains. From 181 182 this study, it can be concluded that more surveillance studies of this kind need to be performed for better understanding of the pattern of drug resistance among routine gut 183 184 colonizers in Asian sub-continent. A thorough and continuous screening for drug-resistant isolates can help in formulating a better antibiotic policy for a hospital, particularly for 185 186 patients admitted in ICUs and oncology units, being more vulnerable to opportunistic infections. 187

188

189 **References**

190

 Khan HA, Baig FK, Mehboob R. Nosocomial infections: Epidemiology, prevention, control and surveillance. Asian Pac J Trop Biomed. 2017 May 1;7(5):478–82.

Mehta Y, Gupta A, Todi S, Myatra S, Samaddar DP, Patil V, et al. Guidelines for prevention of
 hospital acquired infections. Indian J Crit Care Med Peer-Rev Off Publ Indian Soc Crit Care Med.
 2014 Mar;18(3):149–63.

Vincent J-L, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the
 prevalence and outcomes of infection in intensive care units. JAMA. 2009 Dec 2;302(21):2323–
 9.

- Mitchell E. Endogenous vs. Exogenous Infections: It's All About Crowd Control [Internet]. [cited
 2018 Nov 20]. Available from: http://blog.eoscu.com/blog/endogenous-vs.-exogenous infections-its-all-about-crowd-control
- Nichols RL. Preventing Surgical Site Infections: A Surgeon's Perspective Volume 7, Number 2–
 April 2001 Emerging Infectious Diseases journal CDC. [cited 2018 Nov 20]; Available from:
 https://wwwnc.cdc.gov/eid/article/7/2/70-0220_article
- Incidence and Isolation of Bacteria Associated With Nosocomial Urinary Tract Infection (UTI) in
 Sudanese Women SciAlert Responsive Version [Internet]. [cited 2018 Nov 20]. Available from:
 https://scialert.net/fulltextmobile/?doi=jm.2006.534.539
- Guggenbichler JP, Assadian O, Boeswald M, Kramer A. Incidence and clinical implication of nosocomial infections associated with implantable biomaterials – catheters, ventilatorassociated pneumonia, urinary tract infections. GMS Krankenhaushygiene Interdiszip
 [Internet]. 2011 Dec 15 [cited 2018 Nov 20];6(1). Available from:
- 212 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252661/
- Rodríguez-Baño 2015 The Times They Are a-Changin' Carbapenems for Ext.pdf [Internet].
 [cited 2018 Nov 20]. Available from: https://aac.asm.org/content/aac/59/9/5095.full.pdf
- Trivedi M, Trivedi M, Patel V, Soman R, Rodriguez C, Singhal T. The outcome of treating ESBL
 infections with carbapenems vs. non carbapenem antimicrobials. J Assoc Physicians India. 2012
 Aug;60:28–30.
- Codjoe FS, Donkor ES. Carbapenem Resistance: A Review. Med Sci [Internet]. 2017 Dec 21
 [cited 2018 Nov 20];6(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872158/
- Carbapenems: Past, Present, and Future | Antimicrobial Agents and Chemotherapy [Internet].
 [cited 2018 Nov 20]. Available from: https://aac.asm.org/content/55/11/4943
- Rai S, Das D, Niranjan DK, Singh NP, Kaur IR. Carriage prevalence of carbapenem-resistant
 Enterobacteriaceae in stool samples: A surveillance study. Australas Med J. 2014 Feb
 28;7(2):64–7.
- Das P, Singh AK, Pal T, Dasgupta S, Ramamurthy T, Basu S. Colonization of the gut with Gramnegative bacilli, its association with neonatal sepsis and its clinical relevance in a developing country. J Med Microbiol. 2011 Nov;60(Pt 11):1651–60.
- JW BP and B. Opportunistic Infections in Biological Therapy, Risk and Prevention. PubMed NCBI [Internet]. [cited 2018 Nov 28]. Available from:
 https://www.ncbi.nlm.nih.gov/pubmed/27890172
- 232
- 233
- 234
- 235
- 236
- 237

No. of rectal swabs in which CR 29/178 16.2 % isolates were identified CR isolates identified in rectal swabs 13/29 44.8% Only Clinical samples and rectal swabs 12/29 41.3% With similar CR isolates Clinical samples and rectal swabs 4/29 13.7% Clinical samples and rectal swabs 4/29 13.7% with different CR isolates 4/29 13.7% *CR- carbapenem resistant 4/29 13.7% Table 1: Distribution pattern of carbapenem resistant isolates in rectal swabs and clinical samples of different patients. 4/24 243 *CR- carbapenem resistant 5/21 244 5/21 5/21 245 5/21 5/21 246 5/21 5/21 247 5/21 5/21 248 5/21 5/21 250 5/21 5/21 251 5/21 5/21 252 5/21 5/21 254 5/21 5/21		Isolates Number %age						
CR isolates identified in rectal swabs 13/29 44.8% only Clinical samples and rectal swabs 12/29 41.3% With similar CR isolates Clinical samples and rectal swabs 4/29 13.7% Clinical samples and rectal swabs 4/29 13.7% with different CR isolates Image: clinical samples and rectal swabs 1/29 1/27 rCR- carbapenem resistant Image: clinical samples of different patients. Image: clinical samples of different patients. Table 1: Distribution pattern of carbapenem resistant isolates in rectal swabs and clinical samples of different patients. Image: clinical samples of different patients. View Image: clinical samples of different patients. Image: clinical samples of different patients. View Image: clinical samples of different patients. Image: clinical samples of different patients. View Image: clinical samples of different patients. Image: clinical samples of different patients. View Image: clinical samples of different patients. Image: clinical samples of different patients. View Image: clinical samples of different patients. Image: clinical samples of different patients. View Image: clinical samples of different patients. Image: clinical samples of different patients.		No. of rectal swabs in which CI	R 29/178	16.2 %				
only Image:		isolates were identified						
Clinical samples and rectal swabs 12/29 41.3% with similar CR isolates Clinical samples and rectal swabs 4/29 13.7% Clinical samples and rectal swabs 4/29 13.7% with different CR isolates		CR isolates identified in rectal swab	s 13/29	44.8%				
with similar CR isolates image: constraint of carbapenem resistant clinical samples and rectal swabs 4/29 with different CR isolates 13.7% excrement resistant *CR- carbapenem resistant rable 1: Distribution pattern of carbapenem resistant isolates in rectal swabs and clinical samples of different patients. clinical samples of different patients. vincent of carbapenem resistant clinical samples of different patients. vincent of carbapenem resistant vincent o		only						
Clinical samples and rectal swabs 4/29 13.7% with different CR isolates *CR- carbapenem resistant *CR- carbapenem resistant *CR- carbapenem resistant isolates in rectal swabs and clinical samples of different patients.		Clinical samples and rectal swab	s 12/29	41.3%				
with different CR isolates 242 243 *CR- carbapenem resistant 244 245 Table 1: Distribution pattern of carbapenem resistant isolates in rectal swabs and 246 clinical samples of different patients. 247 248 249 250 251 252 253 254 255 256		with similar CR isolates						
 *CR- carbapenem resistant Table 1: Distribution pattern of carbapenem resistant isolates in rectal swabs and clinical samples of different patients. clinical samples of different patients. 		Clinical samples and rectal swab	s 4/29	13.7%				
243 *CR- carbapenem resistant 244 245 246 247 248 249 250 251 252 253 254 255 256		with different CR isolates						
244 245 Table 1: Distribution pattern of carbapenem resistant isolates in rectal swabs and clinical samples of different patients. 247 248 249 250 251 252 253 254 255 256	242							
245 Table 1: Distribution pattern of carbapenem resistant isolates in rectal swabs and clinical samples of different patients. 247	243	*CR- carbapenem resistant						
clinical samples of different patients.	244		1 C -	w.				
	245	Table 1: Distribution pattern of carbapenem resistant isolates in rectal swabs and						
248 249 250 251 252 253 254 255 256	246	clinical samples of different patients.						
249 250 251 252 253 254 255 256	247							
250 251 252 253 254 255 256	248							
251 252 253 254 255 256	249	\sim \times						
252 253 254 255 256	250							
253 254 255 256	251							
254 255 256	252							
254 255 256	253							
255 256	254							
256								
257	257							
258								
259								
260								
261	261							
	262							

- --

Name of organism from	No.	Name of organism (Clinical sample)	
rectal swab			
CRE	01	CRK (Urine)	
CRK	01	CRA (Urine)	
CRE	01	CRE (Urine)	
CRE	01	CRK (Sputum)	

268		æ	- Charles
269	CR- carbapenem resistant	$\langle \langle \rangle$	
270	CRE- carbanenem resistant	E coli	: A

- 270 CRE- carbapenem resistant *E.coli*271 CRK- carbapenem resistant *K. pnuemoniae*
 - CRA- carbapenem resistant A. baumannii
 - CKA- carbapeneni resistant A. buumunuu

274 Table 2: Distribution pattern of dissimilar isolates in rectal swabs and clinical samples.

Name of organism isolated	No.	Clinical sample
from rectal swab and		
clinical sample		
CRE	06	4 from urine & 1 each from Sputum &
		Fluid
CRK	04	2 from Urine & 2 from Sputum
CRP	01	Sputum
CRA	01	Blood

- **CRE-** carbapenem resistant *E.coli* **CRK-** carbapenem resistant *K. pnuemoniae*
- CRP- carbapenem resistant P. aeruginosa
- CRA- carbapenem resistant A. baumannii

Table 3: Distribution pattern of similar isolates in rectal swabs and clinical samples.